Bimekizumab for treating ankylosing spondylitis [ID4011]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Deucravacitinib for treating active psoriatic arthritis [ID6561]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Golimumab biosimilar for Rheumatoid Arthritis, Juvenile Arthritis, Ankylosing Spondylitis, Axial Spondyloarthropathy, Psoriatic Arthritis, and Ulcerative Colitis [ID12208]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ixekizumab for treating enthesitis-related arthritis and juvenile psoriatic arthritis in people 2 to 17 years [ID6590]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tildrakizumab for treating active psoriatic arthritis [ID6724]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC